| Literature DB >> 33285739 |
Yuan Zhang1, Xiao-Hui Li2, Yu-Tian Zhou2, Lu Xiang2, Meng Xiao2, Jian-Shu Guo2, Jing-Wei Zhang3, Guo Chen2.
Abstract
Chronic obstructive pulmonary disease (COPD) patients have increased cardiovascular morbidity and mortality. Apolipoprotein E (ApoE) is involved in chronic inflammation which is the common characteristic of emphysema and cardiovascular disease. ApoE polymorphisms are associated with cardiovascular disorders and atherosclerosis. There is no report about the association between ApoE polymorphism and COPD.A total of 480 COPD patients and 322 controls who were unrelated Chinese Han individuals were enrolled. Rs429358 and rs7412 were genotyped and the associations between ApoE polymorphisms and COPD risk were analyzed by logistic regression analysis. Online software SHEsis were applied to perform linkage disequilibrium (LD) and haplotypes analysis. The interactions of ApoE and environmental factor on COPD susceptibility was analyzed by software MDR3.0.2.No significant association was found between rs429358, rs7412 and COPD under different genetic models. Rs429358 and smoking formed the best model in the MDR analysis. The frequency of E2/E2 phenotype was the lowest in 2 groups. E3/E3 was the most common phenotype, accounting for 69.8% of COPD patients and 68.9% of controls. No statistically difference was identified between the cases and controls under different phenotypes.This was the first genetic association study between ApoE and COPD. No positive association was found in the Chinese Han population. Rs429358 and smoking status existed significant interaction, indicating that both of ApoE and smoking may be involved in the development of COPD disease.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33285739 PMCID: PMC7717833 DOI: 10.1097/MD.0000000000023442
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Characteristics of cases and controls.
| Case | Control | ||
| Male | 251 | 158 | .33 |
| Female | 229 | 164 | |
| Age (Mean ± SD) | 74.70 ± 10.02 | 72.85 ± 10.03 | .62 |
| BMI | 23.84 ± 3.03 | 22.59 ± 5.07 | .45 |
| Smoker + Ex-smoker (%) | 59 | 13 | 2.01x10−16 |
| Non-smoker (%) | 41 | 87 |
BMI = body mass index, SD = standard deviation.
ApoE rs429358 and rs7412 polymorphisms in cases and controls.
| SNPs | Cases N (%) | Controls N (%) | Genetic modelb | OR (95%CI) | Genetic modelb | OR (95%CI) | ||
| rs429358 (T > C) | 480 | 322 | ||||||
| TT | 400 (83.3) | 267 (82.9) | Add | 1.285 (0.870-1.898) | .21 | Hom | 1.101 (0.945-1.284) | .22 |
| TC | 77 (16.1) | 53 (16.5) | Dom | 1.330 (0.867-2.041) | 19 | Het | 1.246 (0.855-1.817) | .25 |
| CC | 3 (0.6) | 2 (0.6) | Rec | 1.349 (0.489-3.721) | .56 | All | 0.975 (0.685–1.387) | .89 |
| rs7412 (C > T) | 480 | 322 | ||||||
| CC | 404 (84.2) | 268 (83.2) | Add | 1.205 (0.826–1.759) | .33 | Hom | 1.056 (0.901–1.238) | .50 |
| TC | 72 (15.0) | 49 (15.2) | Dom | 1.216 (0.788–1.874) | .38 | Het | 1.179 (0.833–1.668) | .35 |
| TT | 4 (0.8) | 5 (1.6) | Rec | 1.493 (0.591–3.771) | 0.40 | All | 1.109 (0.780–1.578) | .56 |
Adjusted for sex, age, BMI and smoking history with logistic regression.
All, allelic model; Add = additive model; Dom = dominant model; Rec = recessive model; Hom = homozygote model; Het = heterozygote model.
Figure 1The Analysis of linkage disequilibrium of 2 SNPs, rs429358 and rs7412.
Haplotype analysis of ApoE in cases and controls.
| Haplotype | Cases N (%) | ControlsN (%) | x2 | OR (95%CI) | |
| C C | 79.51 (0.083) | 53.54 (0.083) | 0.001 | 0.94 [0.77–1.15] | |
| C T | 3.49 (0.004) | 3.46 (0.005) | - | 1.23 [0.97–1.56] | |
| T C | 800.49 (0.834) | 531.46 (0.825) | 0.142 | 0.84 [0.65–1.11] | |
| T T | 76.51 (0.080) | 55.54 (0.086) | 0.228 | ||
| Global test | 960 | 644 | 0.233 | 0.89 |
For each haplotype, alleles were arranged in order of rs429358 - rs7412.
Adjusted for sex, age, BMI and smoking history with logistic regression.
The lowest frequency threshold (LFT) <0.03 were pooled in this part.
The distribution of ApoE protein phenotypes in cases and controls.
| N (%) | E2/ E2 | E2/ E3 | E3/ E3 | E3/ E4 | E4/ E4 | E2/ E4 |
| Cases | 4 (0.8) | 61 (12.7) | 335 (69.8) | 66 (13.8) | 3 (0.6) | 11 (2.3) |
| Controls | 5 (1.6) | 40 (12.4) | 222 (68.9) | 44 (13.7) | 2 (0.6) | 9 (2.8) |
Association between ApoE protein phenotypes and COPD.
| Groups | Case N (%) | Controls N (%) | Case N (%) | Controls N (%) | ||
| ∗E2 | 76 (15.8) | 54 (16.8) | .94 | 65 (13.5) | 45 (14.0) | .97 |
| ∗E3 | 335 (69.8) | 222 (68.9) | 335 (69.8) | 222 (68.9) | ||
| ∗E4 | 69 (14.4) | 46 (14.3) | 80 (16.7) | 55 (17.1) |
P1, P value of model 1: ∗E2 includes E2/E2, E2/E3 and E2/E4 genotypes; ∗E3 includes E3/E3 genotypes; ∗E4 includes E3/E4 and E4/E4 genotypes.
P2, P value of model 2: ∗E2 includes E2/E2 and E2/E3 genotypes; ∗E3 includes E3/E3 genotypes; ∗E4 includes E2/E4, E3/E4 and E4/E4 genotypes.
The MDR analysis of the interaction of ApoE and Smoking.
| Best modela | Testing balanced accuracyb | Cross-validation consistencyc | |
| rs429358- smoking | 0.7321 | 10/10 | 0.00 |
the best combination of variables for each order model.
the ratio of correct classifications to the total classifications in the testing set.
denominator means 10-fold cross validation, numerator means number of times a combination model was selected as the best model in 10-fold cross validation.
P value for testing balanced accuracy using 1000-fold permutation test. P < .05 was significant.